Cabaletta Bio, Inc. (CABA) is a publicly traded company in the Unknown sector. Across all available filings, 15 corporate insiders have executed 58 transactions totaling $34.4M, demonstrating a bearish sentiment with -$7.7M in net insider flow. The most recent transaction on Jan 21, 2026 involved a purchase of 11,312 shares valued at $24.8K.
No significant insider buying has been recorded for CABA in the recent period.
No significant insider selling has been recorded for CABA in the recent period.
Based on recent SEC filings, insider sentiment for CABA is bearish with an Insider Alignment Score of 39/100 and a net flow of -$7.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Cabaletta Bio, Inc. (CABA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 15 insiders are actively trading CABA stock, having executed 58 transactions in the past 90 days. The most active insider is Andrew J. Schwab (Executive), who has made 4 transactions totaling $9.4M.
Get notified when executives and directors at CABA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Binder Gwendolyn | President, Science & Tech. | Purchase | 11,312 | $2.19 | $24.8K | |
| Jan 21, 2026 | J. Chang David | Chief Medical Officer | Purchase | 8,800 | $2.26 | $19.9K | |
| Jan 21, 2026 | Gerard Michael | General Counsel | Purchase | 6,600 | $2.27 | $15.0K | |
| Jan 21, 2026 | Simon Mark | Executive | Purchase | 11,061 | $2.28 | $25.3K | |
| Jan 21, 2026 | Nichtberger Steven | Executive | Purchase | 45,000 | $2.24 | $100.8K | |
| Jan 21, 2026 | Bollard Catherine | Executive | Purchase | 4,405 | $2.27 | $10.0K | |
| Jan 21, 2026 | Gavel Steve | Chief Commercial Officer | Purchase | 22,170 | $2.27 | $50.2K | |
| Jan 21, 2026 | Tomasello Shawn | Executive | Purchase | 22,725 | $2.21 | $50.3K | |
| Jan 19, 2024 | Binder Gwendolyn | Executive | Sale | 700 | $20.33 | $14.2K | |
| Jan 19, 2024 | Binder Gwendolyn | Executive | Sale | 10,300 | $19.54 | $201.3K | |
| Jan 19, 2024 | Binder Gwendolyn | Executive | Option Exercise | 11,000 | $1.01 | $11.1K | |
| Dec 19, 2023 | Binder Gwendolyn | Executive | Option Exercise | 11,000 | $1.01 | $11.1K | |
| Dec 19, 2023 | Binder Gwendolyn | Executive | Sale | 7,868 | $21.76 | $171.2K | |
| Dec 19, 2023 | Binder Gwendolyn | Executive | Sale | 3,132 | $22.22 | $69.6K | |
| Nov 20, 2023 | Binder Gwendolyn | Executive | Sale | 7,458 | $18.02 | $134.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 25 | $21.0M | 60.9% |
Purchase(P) | 17 | $13.3M | 38.6% |
Exercise(M) | 10 | $161.6K | 0.5% |
Conversion(C) | 6 | $0 | 0.0% |
Insider selling pressure at Cabaletta Bio, Inc. has increased, with 15 insiders executing 58 transactions across all time. Total sales of $21.0M significantly outpace purchases of $13.3M, resulting in a net outflow of $7.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.